Please assess the completion status of the following clinical trial:

Trial Title: Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) \[1987\] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[2010\]) at least 16 weeks prior to screening~* ACR global functional status class of 1 to 3~* Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors~* All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening~* Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1)~* Elevated High-sensitivity (hs) CRP and/or ESR~Exclusion Criteria:~* Active serious infection~* History of or active tuberculosis (TB)~* Elevated liver function tests (LFTs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Clazakizumab (Dose # A) (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
- Arm 2: Clazakizumab (Dose # B) (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
- Arm 3: Clazakizumab (Dose # C) (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
- Arm 4: Placebo matching with Clazakizumab (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).